市場調査レポート

商品コード

T細胞療法の市場規模および予測、世界および地域別シェア、動向、成長機会分析レポート範囲：モダリティ別、治療タイプ別、適応症別、地域別

T Cell Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type, Indication, and Geography

出版日: 2023年09月14日
発行: The Insight Partners
ページ情報: 英文 138 Pages
納期: 即納可能

価格

PDF (Single User License)

USD 4,450 653,349円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 6,450 946,989円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 8,450 1,240,629円

レポートPDFを企業内すべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

弊社の最新調査レポート「T細胞療法の市場予測（2020-2030年）、世界および地域別シェア、動向、成長機会分析- モダリティ別、治療タイプ別、適応症別」によると、T細胞療法の市場規模は2022年に27億5,400万米ドルとなり、2030年には90億3,501万米ドルに達すると予測されています。2020～2030年のCAGRは16.0%と推定されます。

がん治療で最も有望な手技のひとつがT細胞療法であり、その応用を拡大するための前臨床および臨床研究が年々増加しています。CAR T細胞療法もまた、がん専門医や学者の間で関心を集めています。世界のがん罹患率の増加とT細胞療法の承認件数の増加が、T細胞療法市場の成長を後押ししています。また、臨床試験中のCAR T細胞療法が増加していることも、今後数年間のT細胞療法市場の成長を後押しすると予想されます。

CAR T細胞療法の現在の状況は、複数の医薬品承認、豊富なパイプライン、進行中の多くの臨床試験により有望です。CAR T細胞療法のパイプラインは様々な臨床開発段階にあり、大手製薬企業はCAR T細胞療法の競争領域におけるパイプラインスペースと将来の成長可能性を前進させるべく取り組んでいます。

2022年11月、Peter MacCallum Cancer CentreとCartherics Pty Ltdは、皮膚T細胞リンパ腫（CTCL）治療のためのCartherics独自の自己CAR T細胞療法（CTH-001）を開発するための共同開発プログラム契約（CDPA）を締結しました。共同研究の主な内容は、CTH-001の臨床規模での製造と第I相臨床試験の実施です。まず、難治性CTCL患者6人を登録する予定です。

JWセラピューティクスの薬剤JWCAR029は、CD19を標的とするCAR T細胞製剤で、進行したリンパ腫や白血病の治療を目的としています。この分子は現在、開発の第II相段階にあります。JWCAR029は当初、再発難治性DLBCLを中心としたB細胞悪性腫瘍の治療薬として研究されています。

ギリアド・サイエンシズ社の薬剤KTE-X19は、現在研究中の自己CD19 CAR T細胞療法です。この薬剤は、T細胞選択とリンパ球濃縮を含むXLPプロセスを用いて製造されます。KTE-X19が研究されている特定のB細胞悪性腫瘍ではリンパ球濃縮が必要です。KTE-X19は現在、成人および小児の急性リンパ性白血病の治療薬として第II相臨床試験段階にあります。FDAはBrexucabtagene autoleucel（旧KTE-X19；Tecartus社）を再発または難治性のマントル細胞リンパ腫（MCL）の成人患者の治療薬として承認しました。

ZUMA-3は、成人の再発／難治性（R/R）B細胞急性リンパ芽球性白血病（B-ALL）を対象に、自己抗CD19 CAR T細胞療法であるKTE-X19を評価する第1/2相試験です。

mRNA CAR T細胞療法であるDescartes-11は、新たに診断された高リスクの多発性骨髄腫（MM）患者を対象とした第II相臨床試験に移行しました。Descartes-11はCAR T細胞分子を一過性に発現し、これらの治療薬に特徴的な毒性を回避します。すでに18人の患者を対象とした第I相試験（NCT03994705）が実施され、その結果、CAR T細胞治療によく見られるサイトカイン放出症候群や神経毒性などの有害事象は認められません。

このように、CAR T細胞療法に関する上記のようなパイプラインは、T細胞療法市場の新たな動向として浮上しています。

T細胞療法市場のモダリティ別洞察

モダリティに基づき、T細胞療法市場は研究用と商業用に区分されます。2022年には、商業化されたセグメントが市場で大きなシェアを占めています。さらに、同セグメントは予測期間中に最も急成長すると予想されます。製品上市の増加と、がん治療におけるT細胞療法の利点に関する認知度の上昇が、商業化セグメントの成長を後押ししています。

治療タイプ別、T細胞療法市場の洞察

治療タイプ別に見ると、T細胞療法市場はCAR T細胞療法とT細胞受容体（TCR）ベースに二分されます。2022年には、CAR T細胞療法分野が市場で大きなシェアを占めています。さらに、同セグメントは予測期間中、大きな成長率で成長します。キメラ抗原受容体（CAR）T細胞治療法では、患者から得たT細胞を人工的に生物工学的に改変し、腫瘍細胞を識別して付着できるCARを発現させる。CAR T細胞分野で事業を展開する企業は、提携、事業拡大、合意、パートナーシップ、新製品発売などの戦略的開拓に乗り出しており、T細胞療法市場の成長を促進しています。例えば、2022年にFDAはJanssen Biotech, Inc.が製造するCARVYKTIを承認しました。CARVYKTIは、キメラ抗原受容体T細胞を意味するCAR-Tと呼ばれる治療法の一種です。CARVYKTI（ciltacabtagene autoleucel）は、多発性骨髄腫と呼ばれる骨髄がんの成人患者に使用される治療薬です。CARVYKTIは、プロテアソーム阻害剤、免疫調節剤、抗 CD38モノクローナル抗体を含む、4種類以上の前治療歴のある再発または難治性の多発性骨髄腫の成人患者を治療します。

世界保健機関（WHO）、欧州がん患者連合（European Cancer Patient Coalition）、米国国立がん研究所（National Cancer Institute）などは、T細胞療法市場に関する報告書を作成する際に参照した主な一次情報および二次情報の一部です。

List Of Tables

Table 1. T Cell Therapy Market Segmentation
Table 2. Global T Cell Therapy Market, by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
Table 3. North America T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 4. North America T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 5. North America T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 6. North America T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 7. US T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 8. US T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 9. US T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 10. US T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 14. Canada T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 19. Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 20. Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 21. Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 22. Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 23. UK T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 24. UK T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 25. UK T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 26. UK T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 27. Germany T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 28. Germany T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 29. Germany T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 30. Germany T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 31. France T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 32. France T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 33. France T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 34. France T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 35. Italy T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 36. Italy T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 37. Italy T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 38. Italy T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 39. Spain T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 40. Spain T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 41. Spain T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 42. Spain T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 43. Rest of Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 44. Rest of Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 45. Rest of Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 46. Rest of Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 47. FDA-Approved Autologous CAR T-Cell Therapies Registered in Asia Pacific
Table 48. Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 49. Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 50. Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 51. Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 52. China T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 53. China T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 54. China T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 55. China T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 56. Japan T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 57. Japan T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 58. Japan T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 59. Japan T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 60. Australia T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 61. Australia T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 62. Australia T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 63. Australia T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 64. South Korea T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 65. South Korea T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 66. South Korea T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 67. South Korea T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 68. Rest of Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 69. Rest of Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 70. Rest of Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 71. Rest of Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 72. Middle East & Africa T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 73. Middle East & Africa T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 74. Middle East & Africa T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 75. Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 76. Saudi Arabia T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 77. Saudi Arabia T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 78. Saudi Arabia T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 79. Saudi Arabia T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 80. Israel T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 81. Israel T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 82. Israel T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 83. Israel T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 84. Rest of Middle East & Africa T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 85. Rest of Middle East & Africa T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 86. Rest of Middle East & Africa T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 87. Rest of Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 88. Brazil T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 89. Brazil T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 90. Brazil T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 91. Brazil T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 92. Recent Organic Growth Strategies in T Cell Therapy Market
Table 93. Recent Inorganic Growth Strategies in the T Cell Therapy Market
Table 94. Glossary of Terms, T Cell Therapy Market

List Of Figures

Figure 1. T Cell Therapy Market Segmentation, By Geography
Figure 2. Global - PEST Analysis
Figure 3. T Cell Therapy Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
Figure 6. T Cell Therapy Market Revenue, Geography (US$ Mn), 2022 - 2030
Figure 7. T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 8. Research: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Commercialized: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 11. CAR T-cell Therapy: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. T-cell Receptor (TCR)-based: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 14. Hematologic Malignancies: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Solid Tumor: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America: T Cell Therapy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 17. North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. North America T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 19. US T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Canada T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Mexico T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Europe T Cell Therapy Market, by Key Country - Revenue, 2022 ($Mn)
Figure 23. Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Europe T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 25. UK T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Germany T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 27. France T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Italy T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. Spain T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. Asia Pacific T Cell Therapy Market, by Key Country - Revenue, 2022 ($Mn)
Figure 32. Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 33. Asia Pacific T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 34. China T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 35. Japan T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 36. Australia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 37. South Korea T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 38. Rest of Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 39. Middle East & Africa T Cell Therapy Market, by Key Country - Revenue, 2022
Figure 40. Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 41. Middle East & Africa T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 42. Saudi Arabia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 43. Israel T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 44. Rest of Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 45. South & Central America T Cell Therapy Market, by Key Country - Revenue, 2022 ($Mn)
Figure 46. South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 47. Brazil T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 48. Pre & Post Covid-19 Impact
Figure 49. Growth Strategies in T Cell Therapy Market

Product Code: TIPRE00024331

According to our new research study on "T Cell Therapy Market Forecast (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis - by Modality, Therapy Type, and Indication," the T cell therapy market size was valued at US$ 2,754.00 million in 2022 and is expected to reach US$ 9,035.01 million by 2030. It is estimated to register a CAGR of 16.0% during 2020-2030.

One of the most promising procedures of cancer treatment is T cell therapy, and every year, an increasing number of pre-clinical and clinical research is being conducted to increase its application. CAR T cell therapy has also generated interest among oncologists and academics. The growing burden of cancer worldwide and an increasing number of T cell therapy approvals drive the growth of the T cell therapy market. Also, rising number of car t-cell therapies in clinical trials is expected to fuel T cell therapy market growth in the coming years.

The current landscape for CAR T-cell therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.

In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics' proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL.

JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.

Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL).

ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).

Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity-adverse events commonly associated with CAR T-cell treatment.

Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the T cell therapy market.

By Modality, T Cell Therapy Market-Based Insights

Based on modality, the T cell therapy market is segmented into research and commercialized. In 2022, the commercialized segment held the larger share of the market. Moreover, the same segment is expected to grow fastest during the forecast period. An increase in product launches and a rise in awareness about the benefits of T cell therapy for cancer treatment fueling the growth of the commercialized segment.

By Therapy Type, T Cell Therapy Market -Based Insights

Based on therapy type, the T cell therapy market is bifurcated into CAR T cell therapy and T cell receptor (TCR)-based. In 2022, the CAR T cell therapy segment held the larger share of the market. Moreover, the same segment will grow at a significant growth rate during the forecast period. In the chimeric antigen receptor (CAR) T cell therapy technique, T cells obtained from patients are artificially bioengineered to express CARs that can identify and attach to the tumor cells. The companies are entering into strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches by companies operating in the CAR T cell segment, fueling the T cell therapy market growth. For instance, in 2022, FDA approved CARVYKTI manufactured by Janssen Biotech, Inc. CARVYKTI is a kind of therapy called CAR-T-which stands for chimeric antigen receptor T cell. CARVYKTI (ciltacabtagene autoleucel) is a treatment used for adult patients with bone marrow cancer called multiple myeloma. CARVYKTI treats adult patients with relapsed or refractory multiple myeloma after four or more former lines of therapy, comprising a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The World Health Organization (WHO), the European Cancer Patient Coalition, and the National Cancer Institute are a few of the major primary and secondary sources referred to while preparing the report on the T cell therapy market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the T cell therapy market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global T cell therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global T cell therapy market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 T Cell Therapy Market, by Geography (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. T Cell Therapy Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 Global PEST Analysis

5. T Cell Therapy Market - Key Industry Dynamics

5.1 Market Drivers:
- 5.1.1 Growing Burden of Cancer Worldwide
- 5.1.2 Increasing Number of T-Cell Therapy Approvals
5.2 Market Restraints
- 5.2.1 Side-effects of CAR T-Cell Therapy
5.3 Market Opportunities
- 5.3.1 Growing Investment in T-Cell Therapy
5.4 Future Trends
- 5.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
5.5 Impact Analysis:

6. T Cell Therapy Market - Global Market Analysis

6.1 T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

7. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality

7.1 Overview
7.2 T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
7.3 Research
- 7.3.1 Overview
- 7.3.2 Research: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Commercialized
- 7.4.1 Overview
- 7.4.2 Commercialized: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

8.1 Overview
8.2 T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
8.3 CAR T-cell Therapy
- 8.3.1 Overview
- 8.3.2 CAR T-cell Therapy: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 T-cell Receptor (TCR)-based
- 8.4.1 Overview
- 8.4.2 T-cell Receptor (TCR)-based: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

9.1 Overview
9.2 T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
9.3 Hematologic Malignancies
- 9.3.1 Overview
- 9.3.2 Hematologic Malignancies: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.3 Global T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
9.4 Solid Tumor
- 9.4.1 Overview
- 9.4.2 Solid Tumor: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

10. T Cell Therapy Market - Geographical Analysis

10.1 North America T Cell Therapy Market, Revenue and Forecast To 2030
- 10.1.1 Overview
- 10.1.2 North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.3 North America: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.1.4 North America: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.1.5 North America: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 10.1.5.1 North America: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.1.5.2 North America T Cell Therapy Market, by Country
  - 10.1.5.3 US
    - 10.1.5.3.1 US T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.5.3.2 US: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.1.5.3.3 US: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.1.5.3.4 US: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.5.3.4.1 US: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.1.5.4 Canada
    - 10.1.5.4.1 Canada T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.5.4.2 Canada: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.1.5.4.3 Canada: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.1.5.4.4 Canada: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.5.4.4.1 Canada: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.1.5.5 Mexico
    - 10.1.5.5.1 Mexico T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.5.5.2 Mexico: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.1.5.5.3 Mexico: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.1.5.5.4 Mexico: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.5.5.4.1 Mexico: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.2 Europe T Cell Therapy Market, Revenue and Forecast to 2030
- 10.2.1 Overview
- 10.2.2 Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.2.3 Europe: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.2.4 Europe: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.2.5 Europe: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 10.2.5.1 Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.2 Europe T Cell Therapy Market, by Country
  - 10.2.5.3 UK
    - 10.2.5.3.1 UK T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.3.2 UK: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.3.3 UK: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.3.4 UK: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.3.4.1 UK: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.4 Germany
    - 10.2.5.4.1 Germany T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.4.2 Germany: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.4.3 Germany: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.4.4 Germany: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.4.4.1 Germany: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.5 France
    - 10.2.5.5.1 France T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.5.2 France: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.5.3 France: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.5.4 France: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.5.4.1 France: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.6 Italy
    - 10.2.5.6.1 Italy T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.6.2 Italy: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.6.3 Italy: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.6.4 Italy: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.6.4.1 Italy: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.7 Spain
    - 10.2.5.7.1 Spain T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.7.2 Spain: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.7.3 Spain: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.7.4 Spain: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.7.4.1 Spain: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.2.5.8 Rest of Europe
    - 10.2.5.8.1 Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.5.8.2 Rest of Europe: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.2.5.8.3 Rest of Europe: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.5.8.4 Rest of Europe: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.5.8.4.1 Rest of Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.3 Asia Pacific T Cell Therapy Market, Revenue and Forecast to 2030
- 10.3.1 Overview
- 10.3.2 Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.3.3 Asia Pacific: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.3.4 Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.3.5 Asia Pacific: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 10.3.5.1 Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.2 Asia Pacific T Cell Therapy Market, by Country
  - 10.3.5.3 China
    - 10.3.5.3.1 China T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.3.2 China: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.3.3 China: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.3.4 China: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.3.4.1 China: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.4 Japan
    - 10.3.5.4.1 Japan T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.4.2 Japan: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.4.3 Japan: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.4.4 Japan: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.4.4.1 Japan: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.5 Australia
    - 10.3.5.5.1 Australia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.5.2 Australia: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.5.3 Australia: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.5.4 Australia: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.5.4.1 Australia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.6 South Korea
    - 10.3.5.6.1 South Korea T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.6.2 South Korea: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.6.3 South Korea: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.6.4 South Korea: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.6.4.1 South Korea: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.3.5.7 Rest of Asia Pacific
    - 10.3.5.7.1 Rest of Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.5.7.2 Rest of Asia Pacific: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.3.5.7.3 Rest of Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.5.7.4 Rest of Asia Pacific: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.5.7.4.1 Rest of Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.4 Middle East & Africa T Cell Therapy Market, Revenue and Forecast to 2030
- 10.4.1 Overview
- 10.4.2 Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.4.3 Middle East & Africa: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
- 10.4.4 Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
- 10.4.5 Middle East & Africa: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 10.4.5.1 Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.4.5.2 Middle East & Africa T Cell Therapy Market, by Country
  - 10.4.5.3 Saudi Arabia
    - 10.4.5.3.1 Saudi Arabia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.3.2 Saudi Arabia: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.4.5.3.3 Saudi Arabia: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.3.4 Saudi Arabia: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.3.4.1 Saudi Arabia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.4.5.4 Israel
    - 10.4.5.4.1 Israel T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.4.2 Israel: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.4.5.4.3 Israel: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.4.4 Israel: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.4.4.1 Israel: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  - 10.4.5.5 Rest of Middle East & Africa
    - 10.4.5.5.1 Rest of Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.5.2 Rest of Middle East & Africa: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.4.5.5.3 Rest of Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.5.4 Rest of Middle East & Africa: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.5.4.1 Rest of Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10.5 South & Central America T Cell Therapy Market, Revenue and Forecast to 2030
- 10.5.1 Overview
- 10.5.2 South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 10.5.2.1 Brazil
    - 10.5.2.1.1 Brazil T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.5.2.1.2 Brazil: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    - 10.5.2.1.3 Brazil: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.5.2.1.4 Brazil: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.5.2.1.4.1 Brazil: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)

11. T Cell Therapy Market-Industry Landscape

11.1 Overview
11.2 Growth Strategies in T Cell Therapy Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Immunocore Holdings Plc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Legend Biotech Corp
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Janssen Global Services LLC
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Gilead Sciences Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Bristol-Myers Squibb Co
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Bluebird Bio Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Novartis AG
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 JW (Cayman) Therapeutics Co Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Cartesian Therapeutics Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Innovent Biologics Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms

T細胞療法の市場規模および予測、世界および地域別シェア、動向、成長機会分析レポート範囲：モダリティ別、治療タイプ別、適応症別、地域別

T Cell Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type, Indication, and Geography

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章 T細胞療法市場情勢

第5章 T細胞療法市場：主要産業力学

第6章 T細胞療法市場- 世界市場分析

第7章 T細胞療法の世界市場T細胞療法の世界市場-2030年までの収益と予測-モダリティ別

第8章 T細胞療法の世界市場：収益と2030年までの予測：治療タイプ別

第9章 T細胞療法の世界市場-2030年までの収益と予測-適応症別

第10章 T細胞療法市場：地域別分析

第11章 T細胞療法市場-業界情勢

第12章企業プロファイル

第13章付録

List Of Tables

List Of Figures

Reasons to Buy:

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. T Cell Therapy Market Landscape

5. T Cell Therapy Market - Key Industry Dynamics

6. T Cell Therapy Market - Global Market Analysis

7. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality

8. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

9. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

10. T Cell Therapy Market - Geographical Analysis

11. T Cell Therapy Market-Industry Landscape

12. Company Profiles

13. Appendix

T細胞療法の市場規模および予測、世界および地域別シェア、動向、成長機会分析レポート範囲：モダリティ別、治療タイプ別、適応症別、地域別

T Cell Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type, Indication, and Geography

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 T細胞療法市場情勢

第5章 T細胞療法市場：主要産業力学

第6章 T細胞療法市場- 世界市場分析

第7章 T細胞療法の世界市場T細胞療法の世界市場-2030年までの収益と予測-モダリティ別

第8章 T細胞療法の世界市場：収益と2030年までの予測：治療タイプ別

第9章 T細胞療法の世界市場-2030年までの収益と予測-適応症別

第10章 T細胞療法市場：地域別分析

第11章 T細胞療法市場-業界情勢

第12章 企業プロファイル

第13章 付録

List Of Tables

List Of Figures

Reasons to Buy:

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. T Cell Therapy Market Landscape

5. T Cell Therapy Market - Key Industry Dynamics

6. T Cell Therapy Market - Global Market Analysis

7. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality

8. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

9. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

10. T Cell Therapy Market - Geographical Analysis

11. T Cell Therapy Market-Industry Landscape

12. Company Profiles

13. Appendix

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第12章企業プロファイル

第13章付録